BRPI0510396B1 - Pestivírus atenuado e seu uso, composição, molécula de ácido nucléico e método para atenuar pestivírus - Google Patents
Pestivírus atenuado e seu uso, composição, molécula de ácido nucléico e método para atenuar pestivírus Download PDFInfo
- Publication number
- BRPI0510396B1 BRPI0510396B1 BRPI0510396-7A BRPI0510396A BRPI0510396B1 BR PI0510396 B1 BRPI0510396 B1 BR PI0510396B1 BR PI0510396 A BRPI0510396 A BR PI0510396A BR PI0510396 B1 BRPI0510396 B1 BR PI0510396B1
- Authority
- BR
- Brazil
- Prior art keywords
- bvdv
- npro
- pestivirus
- mutation
- virus
- Prior art date
Links
- 241000710778 Pestivirus Species 0.000 title claims abstract description 108
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 238000000034 method Methods 0.000 title claims abstract description 35
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 32
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 13
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 13
- 230000035772 mutation Effects 0.000 claims abstract description 126
- 108091026890 Coding region Proteins 0.000 claims abstract description 61
- 230000002238 attenuated effect Effects 0.000 claims abstract description 54
- 102000003886 Glycoproteins Human genes 0.000 claims abstract description 51
- 108090000288 Glycoproteins Proteins 0.000 claims abstract description 51
- 229960005486 vaccine Drugs 0.000 claims abstract description 46
- 230000000694 effects Effects 0.000 claims abstract description 26
- 230000002779 inactivation Effects 0.000 claims abstract description 22
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 claims description 240
- 241001465754 Metazoa Species 0.000 claims description 84
- 150000001413 amino acids Chemical class 0.000 claims description 82
- 241000700605 Viruses Species 0.000 claims description 65
- 208000015181 infectious disease Diseases 0.000 claims description 60
- 108090000623 proteins and genes Proteins 0.000 claims description 44
- 102000006382 Ribonucleases Human genes 0.000 claims description 40
- 108010083644 Ribonucleases Proteins 0.000 claims description 40
- 102000004169 proteins and genes Human genes 0.000 claims description 39
- 230000037430 deletion Effects 0.000 claims description 34
- 238000012217 deletion Methods 0.000 claims description 34
- 239000002773 nucleotide Substances 0.000 claims description 29
- 125000003729 nucleotide group Chemical group 0.000 claims description 29
- 239000002299 complementary DNA Substances 0.000 claims description 25
- 108091005804 Peptidases Proteins 0.000 claims description 17
- 239000004365 Protease Substances 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 12
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 9
- 238000006467 substitution reaction Methods 0.000 claims description 8
- 238000003780 insertion Methods 0.000 claims description 7
- 230000037431 insertion Effects 0.000 claims description 7
- 108020004414 DNA Proteins 0.000 claims description 6
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 6
- 230000028993 immune response Effects 0.000 claims description 6
- 238000010367 cloning Methods 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 4
- 238000013518 transcription Methods 0.000 claims description 4
- 230000035897 transcription Effects 0.000 claims description 4
- 208000004571 Pestivirus Infections Diseases 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000013612 plasmid Substances 0.000 claims description 3
- 238000010839 reverse transcription Methods 0.000 claims description 3
- 238000010348 incorporation Methods 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract description 7
- PPBOKXIGFIBOGK-BDTUAEFFSA-N bvdv Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)C(C)C)[C@@H](C)CC)C1=CN=CN1 PPBOKXIGFIBOGK-BDTUAEFFSA-N 0.000 abstract 4
- 235000001014 amino acid Nutrition 0.000 description 55
- 244000309465 heifer Species 0.000 description 50
- 210000003754 fetus Anatomy 0.000 description 38
- 235000018102 proteins Nutrition 0.000 description 36
- 108010076039 Polyproteins Proteins 0.000 description 34
- 241000283690 Bos taurus Species 0.000 description 30
- 241000710777 Classical swine fever virus Species 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 23
- 108020004705 Codon Proteins 0.000 description 22
- 101800004937 Protein C Proteins 0.000 description 22
- 102000017975 Protein C Human genes 0.000 description 22
- 101800001700 Saposin-D Proteins 0.000 description 22
- 230000001605 fetal effect Effects 0.000 description 22
- 238000011081 inoculation Methods 0.000 description 22
- 210000000265 leukocyte Anatomy 0.000 description 22
- 229960000856 protein c Drugs 0.000 description 22
- 238000002255 vaccination Methods 0.000 description 22
- 239000000523 sample Substances 0.000 description 21
- 238000012360 testing method Methods 0.000 description 21
- 108091028043 Nucleic acid sequence Proteins 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 238000012545 processing Methods 0.000 description 19
- 210000002966 serum Anatomy 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 19
- 206010000210 abortion Diseases 0.000 description 16
- 231100000176 abortion Toxicity 0.000 description 16
- 238000000576 coating method Methods 0.000 description 16
- 102000044159 Ubiquitin Human genes 0.000 description 15
- 108090000848 Ubiquitin Proteins 0.000 description 15
- 239000000872 buffer Substances 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 12
- 238000006386 neutralization reaction Methods 0.000 description 12
- 235000019419 proteases Nutrition 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- 210000002826 placenta Anatomy 0.000 description 11
- 108091033319 polynucleotide Proteins 0.000 description 11
- 102000040430 polynucleotide Human genes 0.000 description 11
- 206010058874 Viraemia Diseases 0.000 description 10
- 230000012010 growth Effects 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- 239000002157 polynucleotide Substances 0.000 description 10
- 230000035935 pregnancy Effects 0.000 description 10
- 230000005540 biological transmission Effects 0.000 description 9
- 239000011248 coating agent Substances 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000003556 assay Methods 0.000 description 8
- 230000004071 biological effect Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 238000011887 Necropsy Methods 0.000 description 7
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 238000012809 post-inoculation Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 108090000565 Capsid Proteins Proteins 0.000 description 6
- 101100379123 Mus musculus Npr1 gene Proteins 0.000 description 6
- 206010037660 Pyrexia Diseases 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 238000010166 immunofluorescence Methods 0.000 description 6
- 229930182817 methionine Natural products 0.000 description 6
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 210000004291 uterus Anatomy 0.000 description 6
- 241000724653 Borna disease virus Species 0.000 description 5
- 102100023321 Ceruloplasmin Human genes 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 238000011888 autopsy Methods 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 238000009395 breeding Methods 0.000 description 5
- 230000001488 breeding effect Effects 0.000 description 5
- 238000011109 contamination Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241000710781 Flaviviridae Species 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 241000709664 Picornaviridae Species 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 238000004820 blood count Methods 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 230000017730 intein-mediated protein splicing Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 102220310404 rs1555202668 Human genes 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- 241000530623 Bovine viral diarrhea virus 2 Species 0.000 description 3
- -1 CP7 amino acid Chemical class 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102100022510 Gamma-aminobutyric acid receptor-associated protein-like 2 Human genes 0.000 description 3
- 101710106568 Gamma-aminobutyric acid receptor-associated protein-like 2 Proteins 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 102100031911 NEDD8 Human genes 0.000 description 3
- 108700004934 NEDD8 Proteins 0.000 description 3
- 101150107958 NEDD8 gene Proteins 0.000 description 3
- 101100532088 Oryza sativa subsp. japonica RUB2 gene Proteins 0.000 description 3
- 101100532090 Oryza sativa subsp. japonica RUB3 gene Proteins 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 241000282898 Sus scrofa Species 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 230000004596 appetite loss Effects 0.000 description 3
- 208000008921 border disease Diseases 0.000 description 3
- 210000000234 capsid Anatomy 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 230000003412 degenerative effect Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000027950 fever generation Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 244000144980 herd Species 0.000 description 3
- 230000000415 inactivating effect Effects 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 235000021266 loss of appetite Nutrition 0.000 description 3
- 208000019017 loss of appetite Diseases 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 102220181341 rs759031496 Human genes 0.000 description 3
- 101150024074 rub1 gene Proteins 0.000 description 3
- 238000003307 slaughter Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- 206010000234 Abortion spontaneous Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000035404 Autolysis Diseases 0.000 description 2
- 101710117545 C protein Proteins 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- 206010008631 Cholera Diseases 0.000 description 2
- 241000511343 Chondrostoma nasus Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 101710144111 Non-structural protein 3 Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241000714203 Rabbit hemorrhagic disease virus Species 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 102100026940 Small ubiquitin-related modifier 1 Human genes 0.000 description 2
- 101710081623 Small ubiquitin-related modifier 1 Proteins 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 206010051511 Viral diarrhoea Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000005860 defense response to virus Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000009027 insemination Effects 0.000 description 2
- 230000010468 interferon response Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000000644 isotonic solution Substances 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- 201000002364 leukopenia Diseases 0.000 description 2
- 231100001022 leukopenia Toxicity 0.000 description 2
- 229940124590 live attenuated vaccine Drugs 0.000 description 2
- 229940023012 live-attenuated vaccine Drugs 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 208000015994 miscarriage Diseases 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 102220001128 rs387906282 Human genes 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000028043 self proteolysis Effects 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 208000000995 spontaneous abortion Diseases 0.000 description 2
- 210000001562 sternum Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000014599 transmission of virus Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical class OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000039813 Border disease virus - BD31 Species 0.000 description 1
- 101500025132 Bos taurus Ubiquitin Proteins 0.000 description 1
- 101500027500 Bos taurus Ubiquitin Proteins 0.000 description 1
- 101500027539 Bos taurus Ubiquitin Proteins 0.000 description 1
- 101500028979 Bos taurus Ubiquitin Proteins 0.000 description 1
- 108700016947 Bos taurus structural-GP Proteins 0.000 description 1
- 101800001603 Capsid protein C Proteins 0.000 description 1
- 208000001726 Classical Swine Fever Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 101800001847 Core protein precursor Proteins 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 101710118188 DNA-binding protein HU-alpha Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101000686777 Escherichia phage T7 T7 RNA polymerase Proteins 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 208000012766 Growth delay Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010056254 Intrauterine infection Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 101800000021 N-terminal protease Proteins 0.000 description 1
- 101710144128 Non-structural protein 2 Proteins 0.000 description 1
- 101800001020 Non-structural protein 4A Proteins 0.000 description 1
- 101800001019 Non-structural protein 4B Proteins 0.000 description 1
- 101800001014 Non-structural protein 5A Proteins 0.000 description 1
- 101710199667 Nuclear export protein Proteins 0.000 description 1
- 241000209094 Oryza Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 230000007022 RNA scission Effects 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000831652 Salinivibrio sharmensis Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108700010756 Viral Polyproteins Proteins 0.000 description 1
- 108700022715 Viral Proteases Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 210000002718 aborted fetus Anatomy 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 230000002886 autophagic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000001986 peyer's patch Anatomy 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000001296 transplacental effect Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24361—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004025452.4 | 2004-05-19 | ||
| DE102004025452A DE102004025452A1 (de) | 2004-05-19 | 2004-05-19 | Vakzine enthaltend BVDV |
| PCT/EP2005/005377 WO2005111201A1 (en) | 2004-05-19 | 2005-05-18 | Vaccine comprising an attenuated pestivirus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0510396A BRPI0510396A (pt) | 2007-11-13 |
| BRPI0510396B1 true BRPI0510396B1 (pt) | 2020-08-18 |
Family
ID=34967522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0510396-7A BRPI0510396B1 (pt) | 2004-05-19 | 2005-05-18 | Pestivírus atenuado e seu uso, composição, molécula de ácido nucléico e método para atenuar pestivírus |
Country Status (26)
| Country | Link |
|---|---|
| EP (1) | EP1751276B9 (enExample) |
| JP (2) | JP5006782B2 (enExample) |
| KR (1) | KR100908798B1 (enExample) |
| CN (2) | CN103352030B (enExample) |
| AR (2) | AR049176A1 (enExample) |
| AT (1) | ATE420949T1 (enExample) |
| AU (1) | AU2005243488B2 (enExample) |
| BR (1) | BRPI0510396B1 (enExample) |
| CA (1) | CA2561719C (enExample) |
| CY (4) | CY1109036T1 (enExample) |
| DE (2) | DE102004025452A1 (enExample) |
| DK (1) | DK1751276T5 (enExample) |
| ES (1) | ES2321210T3 (enExample) |
| FR (3) | FR15C0044I2 (enExample) |
| HU (2) | HUS1500033I1 (enExample) |
| LU (3) | LU92749I2 (enExample) |
| ME (1) | ME01119B (enExample) |
| MX (1) | MXPA06013298A (enExample) |
| NL (3) | NL300743I1 (enExample) |
| NZ (1) | NZ552088A (enExample) |
| PL (1) | PL1751276T3 (enExample) |
| PT (1) | PT1751276E (enExample) |
| RS (1) | RS50753B9 (enExample) |
| SI (1) | SI1751276T1 (enExample) |
| UY (1) | UY28905A1 (enExample) |
| WO (1) | WO2005111201A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7179473B2 (en) | 1998-06-05 | 2007-02-20 | Boehringer Ingelheim Vetmedica Gmbh | Attenuated pestiviruses |
| US7135561B2 (en) | 2001-09-06 | 2006-11-14 | Boehringer Ingelheim Vetmedica Gmbh | Infectious bovine viral diarrhea virus clone |
| US20090068223A1 (en) | 2005-11-15 | 2009-03-12 | Boehringer Ingelheim Vetmedica, Inc. | Combination vaccine comprising an attenuated bovine viral diarrhea virus |
| CL2007002704A1 (es) | 2006-09-22 | 2008-05-30 | Intervet Int Bv | Mutante de un pestivirus de una cepa citopatogenica con deleciones en la region codificante de la proteina npro del virus; vacuna que la comprende; y su uso para proteger al ganado vacuno contra la infeccion con un pestivirus tipo silvestre. |
| CL2008003202A1 (es) | 2007-10-29 | 2009-11-27 | Boehringer Ingelheim Vetmedica Inc | Composicion inmunogenica que comprende bacterias vivas de mycoplasma bovis atenuada avirulenta. |
| UY31930A (es) * | 2008-06-25 | 2010-01-29 | Boheringer Ingelheim Pharma Kg | Pestivirus atenuados recombinantes, en particular a csfv, bvdv o bdv atenuado recombinante |
| SG10201506597RA (en) | 2008-10-31 | 2015-10-29 | Boehringer Ingelheim Vetmed | Use Of Various Antigens Including Antigens From Mycoplasma Bovis In Multivalent Vaccine Composition |
| US8846054B2 (en) | 2009-01-09 | 2014-09-30 | Boehringer Ingelheim Vetmedica, Inc. | Method of treating pregnant cows and/or heifers |
| UY32570A (es) | 2009-04-24 | 2010-11-30 | Boehringer Ingelheim Vetmed | Vacuna viva modificada de mycoplasma bovis mejorada |
| BR112013006515B1 (pt) | 2010-09-21 | 2020-04-28 | Intervet Int Bv | vacina de combinação, e, método para a fabricação de uma vacina de combinação |
| JP6589159B2 (ja) * | 2014-04-01 | 2019-10-16 | 共立製薬株式会社 | 新規ネコモルビリウイルス株、不活化ワクチン製剤、並びにネコモルビリウイルス感染症予防方法 |
| ES2757927T3 (es) * | 2014-05-23 | 2020-04-30 | Boehringer Ingelheim Vetmedica Gmbh | Virus de la peste porcina clásica (VPPC) recombinante que comprende sustituciones en el epítopo TAV de la proteína E2 |
| CN105779499B (zh) * | 2016-03-23 | 2019-11-19 | 江苏科技大学 | 重组杆状病毒和其应用及构建该重组杆状病毒的载体 |
| CN107823639B (zh) * | 2017-11-10 | 2020-10-02 | 齐鲁动物保健品有限公司 | 牛病毒性腹泻病毒灭活疫苗及其制备方法 |
| CN108707190B (zh) * | 2018-04-18 | 2021-07-13 | 中国科学院武汉病毒研究所 | 猪瘟病毒ns5b蛋白保真度突变体及其应用 |
| CN114853912B (zh) * | 2022-05-24 | 2023-06-13 | 中国农业科学院兰州兽医研究所 | 一种牛病毒性腹泻病毒e2-e0融合蛋白、制备方法及应用 |
| CN115960847B (zh) * | 2023-01-11 | 2024-06-14 | 青岛大学 | 小分子依赖的内含肽自剪接系统在制备减毒活疫苗中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6168942B1 (en) * | 1998-11-10 | 2001-01-02 | Pfizer Inc. | Attenuated forms of bovine viral diarrhea virus |
| EP1104676A1 (en) * | 1999-11-30 | 2001-06-06 | Boehringer Ingelheim Vetmedica Gmbh | Safe attenuated bovine viral diarrhea viruses for use in pregnant cows |
| CA2363493C (en) * | 2000-11-22 | 2006-06-06 | Xuemei Cao | Attenuated forms of bovine viral diarrhea virus |
| DE10143813A1 (de) * | 2001-09-06 | 2003-04-10 | Boehringer Ingelheim Vetmed | Infektiöser Rindervirusdiarrhoe-Virusklon |
-
2004
- 2004-05-19 DE DE102004025452A patent/DE102004025452A1/de not_active Withdrawn
-
2005
- 2005-05-18 CN CN201310269097.1A patent/CN103352030B/zh not_active Expired - Lifetime
- 2005-05-18 AR ARP050102032A patent/AR049176A1/es active IP Right Grant
- 2005-05-18 AT AT05741681T patent/ATE420949T1/de active
- 2005-05-18 NZ NZ552088A patent/NZ552088A/en not_active IP Right Cessation
- 2005-05-18 SI SI200530619T patent/SI1751276T1/sl unknown
- 2005-05-18 KR KR1020067026800A patent/KR100908798B1/ko not_active Expired - Lifetime
- 2005-05-18 WO PCT/EP2005/005377 patent/WO2005111201A1/en not_active Ceased
- 2005-05-18 PL PL05741681T patent/PL1751276T3/pl unknown
- 2005-05-18 EP EP05741681.0A patent/EP1751276B9/en not_active Expired - Lifetime
- 2005-05-18 DK DK05741681.0T patent/DK1751276T5/da active
- 2005-05-18 JP JP2007517077A patent/JP5006782B2/ja not_active Expired - Lifetime
- 2005-05-18 DE DE602005012381T patent/DE602005012381D1/de not_active Expired - Lifetime
- 2005-05-18 CN CN200580024345XA patent/CN1989240B/zh not_active Expired - Lifetime
- 2005-05-18 ME MEP-2009-56A patent/ME01119B/me unknown
- 2005-05-18 UY UY28905A patent/UY28905A1/es not_active IP Right Cessation
- 2005-05-18 ES ES05741681T patent/ES2321210T3/es not_active Expired - Lifetime
- 2005-05-18 MX MXPA06013298A patent/MXPA06013298A/es active IP Right Grant
- 2005-05-18 CA CA2561719A patent/CA2561719C/en not_active Expired - Lifetime
- 2005-05-18 RS RS20090106A patent/RS50753B9/sr unknown
- 2005-05-18 PT PT05741681T patent/PT1751276E/pt unknown
- 2005-05-18 BR BRPI0510396-7A patent/BRPI0510396B1/pt active IP Right Grant
- 2005-05-18 AU AU2005243488A patent/AU2005243488B2/en not_active Expired
-
2009
- 2009-04-10 CY CY20091100429T patent/CY1109036T1/el unknown
-
2011
- 2011-11-11 JP JP2011247652A patent/JP5562316B2/ja not_active Expired - Lifetime
-
2015
- 2015-06-16 NL NL300743C patent/NL300743I1/nl unknown
- 2015-06-16 NL NL300744C patent/NL300744I2/nl unknown
- 2015-06-16 NL NL300745C patent/NL300745I1/nl unknown
- 2015-06-19 FR FR15C0044C patent/FR15C0044I2/fr active Active
- 2015-06-19 CY CY2015023C patent/CY2015023I2/el unknown
- 2015-06-19 LU LU92749C patent/LU92749I2/xx unknown
- 2015-06-19 FR FR15C0043C patent/FR15C0043I2/fr active Active
- 2015-06-19 CY CY2015022C patent/CY2015022I2/el unknown
- 2015-06-19 LU LU92748C patent/LU92748I2/xx unknown
- 2015-06-19 FR FR15C0042C patent/FR15C0042I2/fr active Active
- 2015-06-19 CY CY2015021C patent/CY2015021I2/el unknown
- 2015-06-19 HU HUS1500033C patent/HUS1500033I1/hu unknown
- 2015-06-19 LU LU92747C patent/LU92747I2/xx unknown
- 2015-06-19 HU HUS1500031 patent/HUS1500031I1/hu unknown
-
2016
- 2016-04-28 AR ARP160101219A patent/AR104448A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5562316B2 (ja) | 弱毒ペスチウイルスを含むワクチン | |
| EP2303320B1 (en) | Attenuated pestivirus | |
| US20090226488A1 (en) | Vaccine comprising an attenuated pestivirus | |
| BRPI0618593A2 (pt) | combinação de vacina compreendendo um vìrus da diarréia viral bovina atenuado | |
| ES2253457T3 (es) | Pestivirus atenuados. | |
| KR101097547B1 (ko) | 마킹된 소 바이러스성 설사 바이러스 백신 | |
| Palomares-Naveda | Immunopathogenesis, prevention and control of Bovine viral diarrhea virus | |
| MX2008006162A (en) | Combination vaccine comprising an attenuated bovine viral diarrhea virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B09W | Correction of the decision to grant [chapter 9.1.4 patent gazette] |
Free format text: RETIFIQUE-SE (9.1.4). |
|
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/08/2020, OBSERVADAS AS CONDICOES LEGAIS. |